Financial Contrast: AC Immune (NASDAQ:ACIU) versus Viridian Therapeutics (NASDAQ:VRDN)

Viridian Therapeutics (NASDAQ:VRDN) and AC Immune (NASDAQ:ACIU) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Volatility & Risk

Viridian Therapeutics has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, AC Immune has a beta of 1.64, suggesting that its share price is 64% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Viridian Therapeutics and AC Immune, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1	1	13	0	2.80
AC Immune	1	1	2	0	2.25

Viridian Therapeutics presently has a consensus target price of $42.21, suggesting a potential upside of 48.59%. AC Immune has a consensus target price of $10.00, suggesting a potential upside of 233.33%. Given AC Immune’s higher probable upside, analysts clearly believe AC Immune is more favorable than Viridian Therapeutics.

Institutional and Insider Ownership

51.4% of AC Immune shares are owned by institutional investors. 1.6% of Viridian Therapeutics shares are owned by insiders. Comparatively, 4.6% of AC Immune shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Viridian Therapeutics and AC Immune’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-483.57%	-83.25%	-50.38%
AC Immune	-1,642.89%	-84.32%	-35.94%

Earnings and Valuation

This table compares Viridian Therapeutics and AC Immune”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$70.85 million	40.98	-$342.60 million	($3.29)	-8.64
AC Immune	$31.02 million	9.71	-$57.83 million	($0.84)	-3.57

AC Immune has lower revenue, but higher earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Summary

AC Immune beats Viridian Therapeutics on 8 of the 14 factors compared between the two stocks.

About Viridian Therapeutics

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.